Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall ...

Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending in the fourth quarter of fiscal 2024 as trials for its treatment ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...

Hospital-based care for hallucinogen use is associated with increased mortality, according to a study published online March ...

Total Revenue of $426.5 Million, a 65% YoY IncreaseFY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Emergent Biosolutions Inc. (EBS) on Monday reported a loss of $31.3 million in its fourth quarter. The Gaithersburg, Maryland-based company said it ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Ocular Therapeutix shares were down 9%, to $6.50, after the company reported a fourth-quarter loss that was wider than expected.

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...